Tools hub
Financial Calculators
Private, in-browser — no account required.
Recent
quick returnPopular searches
live pathsNYSE · Healthcare
$152.44
▲ +$17.27(+12.78%)2:59 PM ET - vs previous closeiQuote as of Aug 19, 2026, 2:59 PM EDT
Realtime NYSE quote as of Aug 19, 2026, 2:59 PM EDT.
Market data source
Chart
Latest 1D session
1Y · weekly bars · USD · Live $152.44 · 255 pts
Live checkTrade access
Affiliate disclosure: TECHi may earn a commission on links to broker partners. Read more.
Investor playbook
The current snapshot gives bulls more to work with, but the watch list still controls timing.
Use it for
Entry timing, risk check, and catalyst scan
What has to keep working for US investors to stay interested.
Trend support
+34.3%Current price is above the 200-day average.
Cash yield
4.3%$16.06B free-cash-flow base.
Where the dashboard says the thesis can break or get crowded.
Premium multiple
122.94Trailing P/E is high enough that earnings misses can matter fast.
Catalysts and positioning checks that are not duplicate live-pulse metrics.
Latest catalyst
SeekingAlphaMerck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead
The playbook is derived from quote, analyst, financial, news, and trend snapshots. It is a research workflow aid, not a buy or sell recommendation.
As of Aug 19, 2026, 2:59 PM EDT, Merck & Company, Inc. (MRK) traded at $152.44, a +12.78% move versus the prior close, ranging between $144.90 and $152.60 intraday, and on volume of 24.57M shares. The stock has traded between $77.58 and $152.60 over the past 52 weeks, carries a market capitalization of $376.1B, trades at 122.94x trailing earnings, and yields 2.5% in dividends. Sell-side analysts rate MRK Buy across 36 ratings and carry an average price target of $137.73 (-9.65% implied versus the last quote). MRK's record close stands at $151.80, set on Aug 19, 2026.
Buy analyst tone. Latest catalyst: Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead (SeekingAlpha).
Balanced watch. Track record validation (89/100) is the strongest signal; news sentiment (8/100) is the main constraint. Model confidence is 65/100 — some inputs are unavailable, so treat this as a directional research screen rather than a forecast. Long-term secular context is tracked separately: 1 Year +81.2% total; yesterday +10.2%. Comparable past signals have verified against subsequent prices 14.4% of the time.
Expected-return math is scaled by beta and realized volatility before confidence is applied.
Short-horizon expected moves are volume-weighted so thin moves get less credit than confirmed tape.
Sector momentum is included beside the broader market regime.
| Enterprise value | $423.15B |
| Price / sales | 5.65 |
| Price / book | 8.97 |
| Return on assets | 2.44% |
| EPS (TTM) | $1.24 |
| Beta (5Y) | 0.21 |
Benchmark context
Compare against its sector ETF and the broad market.
Help · FAQ
3 answers covering latest price, analyst view, and sector context.
TECHi displays provider-supplied values only when the corresponding field is present.
TECHi.com